Emcure Pharmaceuticals Limited (BOM:544210)
India · Delayed Price · Currency is INR 1,961.80
+46.60 (2.43%)
At close: Sep 10, 2026
Emcure Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 375,358 | 302,490 | 203,202 | - | - | - | |
Market Cap Growth | 42.98% | 48.86% | - | - | - | - |
Enterprise Value | 389,362 | 315,376 | 214,615 | - | - | - |
Last Close Price | 1976.75 | 1592.86 | 1068.51 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 37.11 | 32.72 | 29.82 | - | - | - |
PS Ratio | 3.88 | 3.29 | 2.57 | - | - | - |
PB Ratio | 7.54 | 6.08 | 4.38 | - | - | - |
P/TBV Ratio | 9.75 | 7.86 | 5.81 | - | - | - |
P/FCF Ratio | 64.39 | 51.89 | 32.26 | - | - | - |
P/OCF Ratio | 39.78 | 32.06 | 23.86 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 4.02 | 3.43 | 2.72 | - | - | - |
EV/EBITDA Ratio | 20.44 | 18.31 | 15.20 | - | - | - |
EV/EBIT Ratio | 26.53 | 22.96 | 19.79 | - | - | - |
EV/FCF Ratio | 66.79 | 54.10 | 34.07 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.31 | 0.31 | 0.22 | 0.75 | 0.88 | 1.05 |
Debt / EBITDA Ratio | 0.80 | 0.86 | 0.70 | 1.91 | 1.99 | 1.68 |
Debt / FCF Ratio | - | 2.61 | 1.62 | 2.84 | 6.55 | 5.69 |
Net Debt / Equity Ratio | 0.28 | 0.28 | 0.17 | 0.60 | 0.71 | 0.97 |
Net Debt / EBITDA Ratio | 0.72 | 0.80 | 0.56 | 1.58 | 1.65 | 1.59 |
Net Debt / FCF Ratio | - | 2.38 | 1.26 | 2.27 | 5.30 | 5.27 |
Asset Turnover | - | 1.03 | 0.99 | 0.92 | 0.94 | 0.91 |
Inventory Turnover | - | 1.68 | 1.80 | 1.66 | 1.54 | 1.47 |
Quick Ratio | - | 0.71 | 0.86 | 0.75 | 0.72 | 0.51 |
Current Ratio | - | 1.43 | 1.71 | 1.33 | 1.27 | 1.16 |
Return on Equity (ROE) | - | 19.57% | 18.23% | 18.28% | 23.59% | 31.35% |
Return on Assets (ROA) | - | 9.62% | 8.45% | 7.92% | 9.04% | 10.54% |
Return on Invested Capital (ROIC) | 16.93% | 17.04% | 15.16% | 13.97% | 15.92% | 18.40% |
Return on Capital Employed (ROCE) | - | 24.10% | 19.50% | 20.00% | 25.20% | 35.00% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.69% | 3.06% | 3.35% | - | - | - |
FCF Yield | 1.55% | 1.93% | 3.10% | - | - | - |
Dividend Yield | 0.19% | 0.23% | 0.28% | - | - | - |
Payout Ratio | - | 6.15% | - | 10.89% | 6.80% | 8.19% |
Buyback Yield / Dilution | -0.24% | -1.33% | -3.41% | -0.01% | - | - |
Total Shareholder Return | -0.06% | -1.11% | -3.13% | -0.01% | - | - |